Prot #1199.247: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Project: Research project

Project Details

StatusActive
Effective start/end date8/16/178/16/20

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1199.247)